1. Home
  2. WRN vs ESPR Comparison

WRN vs ESPR Comparison

Compare WRN & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WRN
  • ESPR
  • Stock Information
  • Founded
  • WRN 2006
  • ESPR 2008
  • Country
  • WRN Canada
  • ESPR United States
  • Employees
  • WRN N/A
  • ESPR N/A
  • Industry
  • WRN Metal Mining
  • ESPR Biotechnology: Pharmaceutical Preparations
  • Sector
  • WRN Basic Materials
  • ESPR Health Care
  • Exchange
  • WRN Nasdaq
  • ESPR Nasdaq
  • Market Cap
  • WRN 248.0M
  • ESPR 220.0M
  • IPO Year
  • WRN N/A
  • ESPR 2013
  • Fundamental
  • Price
  • WRN $1.33
  • ESPR $2.05
  • Analyst Decision
  • WRN Strong Buy
  • ESPR Buy
  • Analyst Count
  • WRN 1
  • ESPR 6
  • Target Price
  • WRN $4.00
  • ESPR $6.50
  • AVG Volume (30 Days)
  • WRN 407.5K
  • ESPR 6.7M
  • Earning Date
  • WRN 08-08-2025
  • ESPR 08-05-2025
  • Dividend Yield
  • WRN N/A
  • ESPR N/A
  • EPS Growth
  • WRN N/A
  • ESPR N/A
  • EPS
  • WRN N/A
  • ESPR N/A
  • Revenue
  • WRN N/A
  • ESPR $268,125,000.00
  • Revenue This Year
  • WRN N/A
  • ESPR $6.10
  • Revenue Next Year
  • WRN N/A
  • ESPR N/A
  • P/E Ratio
  • WRN N/A
  • ESPR N/A
  • Revenue Growth
  • WRN N/A
  • ESPR N/A
  • 52 Week Low
  • WRN $0.90
  • ESPR $0.69
  • 52 Week High
  • WRN $1.42
  • ESPR $3.94
  • Technical
  • Relative Strength Index (RSI)
  • WRN 58.21
  • ESPR 72.51
  • Support Level
  • WRN $1.20
  • ESPR $1.74
  • Resistance Level
  • WRN $1.30
  • ESPR $1.97
  • Average True Range (ATR)
  • WRN 0.05
  • ESPR 0.16
  • MACD
  • WRN 0.00
  • ESPR 0.04
  • Stochastic Oscillator
  • WRN 88.72
  • ESPR 84.02

About WRN Western Copper and Gold Corporation

Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Share on Social Networks: